February 16, 2026 (Global) – Waters Corporation has officially completed its strategic combination with Becton, Dickinson and Company’s (BD) Biosciences and Diagnostic Solutions businesses, creating a broader life sciences and diagnostics leader with expanded capabilities across analytical science, clinical diagnostics, research and regulated testing. The deal, which closed earlier this month, strengthens Waters’ position in high‑growth markets and broadens its portfolio of solutions for pharmaceutical, biotechnology, clinical and environmental applications.
“The completion of this combination represents an exciting milestone for Waters and our customers,” said Udit Batra, President and CEO of Waters Corporation. “By integrating BD’s Biosciences and Diagnostic Solutions businesses with our deep expertise in analytical technologies, we are well‑positioned to deliver innovative solutions that address complex scientific and clinical challenges across the life sciences ecosystem.”
The Waters–BD combination brings together Waters’ world‑class analytical instrumentation — including liquid chromatography, mass spectrometry and advanced separations — with BD’s strengths in flow cytometry, immunoassays, microbiology and molecular diagnostics. The unified entity aims to offer comprehensive end‑to‑end solutions that support discovery, development, quality control, and clinical testing workflows at scale.
Strategic Expansion and Market Impact
- Enhanced analytical and diagnostic portfolio – combining Waters’ analytical platforms with BD’s biosciences and diagnostics technologies to deliver more robust workflows.
- Four specialised divisions launched — Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences — to better serve diverse market segments.
- Increased R&D investment and innovation capacity — the expanded company plans to accelerate development of next‑generation products across life sciences and diagnostics.
- Stronger global market reach — the combined business aims to expand its footprint in regulated testing, clinical diagnostics and high‑throughput laboratory environments.
- Broader solutions for pharmaceutical and biotech industries — integrating analytical and diagnostic capabilities to support faster, more reliable results in drug discovery and development.
Waters highlights that the combination, structured as a Reverse Morris Trust transaction, was completed with Waters shareholders owning a majority stake in the new entity while BD shareholders retain significant ownership. This structure is designed to unlock long‑term value for both companies’ investors and set the stage for sustainable growth.
Industry analysts observe that the expanded Waters company is now better positioned to meet the evolving needs of life sciences and clinical researchers, particularly in complex analytical workflows, high‑volume diagnostic testing and regulated environments. The integration also underscores a broader industry trend toward convergence of analytical science and clinical diagnostics, helping laboratories streamline operations and accelerate insights.
